Nail Fungus, or Onychomycosis, occurs when fungi infect nails of feet or hands. According to Podiatry Today, 35 million people in the US have Onychomycosis including 26% of diabetics. The US market is $1.6 Billion, with a global market anticipated to grow to $3.6 billion by 2010. Topical treatments cannot reach the fungal source in the nailbed. Systemic oral medications such as Lamisil (62% of market share) work but carry a very serious side effect profile.
MACROESIS™ technology pushes an existing, registered, anti-fungal agent into and through the nail to attack the root source of the fungus. The result is a very efficacious localized treatment with no side effects delivered at a low cost. MACRORESIS™ can treat from mild cases to severe cases such as distal infection (in the nail bed) which has been only treatable with systemics.
Iontophoresis has been available for 20 years. It uses low voltage direct current (DC) to increase drug flux across the skin. This active drug delivery technology is limited to a small class of drugs that are polarized and small enough to permeate the skin.
electrochemistry and targeted
drug delivery to circumvent the
limitations of iontophoresis,
pushing antifungal drugs right
through the nail cuticle to the
actual location of the fungus
growth. This would be the
first treatment option to
directly target nail fungus at